Panbela Applies to List on CBOE

Dow Jones04-19

By Stephen Nakrosis

Panbela Therapeutics, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options Exchange.

The stock, which began trading over the counter April 17 under the symbol PBLA, would trade under the same symbol on the CBOE, the company said.

The company filed for a stock and warrant offering, but said the offering wouldn't be consummated unless its common stock is approved for listing on the CBOE.

In March, a Nasdaq hearings panel said it decided to delist Panbela's common stock because the company didn't satisfy a minimum $2.5 million stockholders' equity requirement, Panbela said.

The company said it is developing disruptive therapeutics to treat patients with urgent unmet medical needs. Its pipeline consists of assets focusing on treatment of familial adenomatous polyposis and various cancers.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

April 18, 2024 17:23 ET (21:23 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428528419?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428528419","market":"fut","top_or_hot":-1,"title":"Panbela Applies to List on CBOE","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Panbela <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options Exchange. \n</p>\n<p>\n  The stock, which began trading over the counter April 17 under the symbol PBLA, would trade under the same symbol on the CBOE, the company said. \n</p>\n<p>\n  The company filed for a stock and warrant offering, but said the offering wouldn't be consummated unless its common stock is approved for listing on the CBOE. \n</p>\n<p>\n  In March, a Nasdaq hearings panel said it decided to delist Panbela's common stock because the company didn't satisfy a minimum $2.5 million stockholders' equity requirement, Panbela said. \n</p>\n<p>\n  The company said it is developing disruptive therapeutics to treat patients with urgent unmet medical needs. Its pipeline consists of assets focusing on treatment of familial adenomatous polyposis and various cancers. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 18, 2024 17:23 ET (21:23 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Panbela Applies to List on CBOE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPanbela Applies to List on CBOE\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 05:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Panbela Therapeutics, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2428528419","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428528419","pubTimestamp":1713475380,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Panbela Therapeutics, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options Exchange.The stock, which began trading over the counter April 17 under the symbol PBLA, would trade under the same symbol on the CBOE, the company said.The company filed for a stock and warrant offering, but said the offering wouldn't be consummated unless its common stock is approved for listing on the CBOE.In March, a Nasdaq hearings panel said it decided to delist Panbela's common stock because the company didn't satisfy a minimum $2.5 million stockholders' equity requirement, Panbela said.The company said it is developing disruptive therapeutics to treat patients with urgent unmet medical needs. Its pipeline consists of assets focusing on treatment of familial adenomatous polyposis and various cancers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","PBLA":"Panbela Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","CBOE":"芝加哥期权交易所","BK4532":"文艺复兴科技持仓"},"translate_title":"潘贝拉申请在CBOE上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBOE":1,"PBLA":0.9,"NQmain":0.66},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Panbela Therapeutics, whose shares were recently delisted from the Nasdaq, said Thursday it will seek to list on the US Equity Listings Tier II Chicago Board of Options Exchange. \n\n\n  The stock, which began trading over the counter April 17 under the symbol PBLA, would trade under the same symbol on the CBOE, the company said. \n\n\n  The company filed for a stock and warrant offering, but said the offering wouldn't be consummated unless its common stock is approved for listing on the CBOE. \n\n\n  In March, a Nasdaq hearings panel said it decided to delist Panbela's common stock because the company didn't satisfy a minimum $2.5 million stockholders' equity requirement, Panbela said. \n\n\n  The company said it is developing disruptive therapeutics to treat patients with urgent unmet medical needs. Its pipeline consists of assets focusing on treatment of familial adenomatous polyposis and various cancers. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 18, 2024 17:23 ET (21:23 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428528419"}